MarketBeat Ratings released the stock reports of FGEN(FibroGen, Inc.). According to the report, the average rating earned by the company is “Hold”. Currently, the total number of analysts who are acting as a cover to the company is ten.
According to the reports of two analysts of investment, the rate of the stock of FGEN is recommended for sell. Three analysts have recommended a hold for the company. And a total of four analysts have given the recommendation of “buy”. As per the updated average price target of one year, the updated number given for the stock coverage of the year 2020 is 50 USD.
FGEN’s Rating Downgraded By Jefferies
The stock of FGEN is taken up as a subject by a bunch of reports from analysts. The price target of the company that got lowered by SVB Leerink was from 91.00 USD to 64.00 USD. They also rated the company for a report of research. The rating was “outperform”. This came out this Tuesday on the 2nd of March.
According to Zacks Investment Research, FGEN got a downgraded rating in their research report. It fell from hold to sell. This came out this Monday on the 22nd of February. The company got initiation of coverage on the 1st of February. The price target according to them is 58.00 USD along with the rating of “buy.”
FGEN got a downgrade rating from the Jefferies Financial Group. It fell from buy to sell. The price target for the stock of the company also got lowered by them. It fell from 75.00 USD to the amount of 45.00 USD. This report came out this Tuesday on the 2nd of March.
Pat Cotroneo, the CFO, sold a total of 3,068 shares from the stock of the firm. This took place in a transaction that was held on the 15th of December. The price at which it was sold was 43.60 USD. The amount of the total transaction was 133,764.80 USD.
